ReviewCurrent opinion in rheumatology2020
Preclinical rheumatoid arthritis and rheumatoid arthritis prevention.
Review in Current opinion in rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Sinomenine ameliorates rheumatoid arthritis in rodent models: a systematic review and meta-analysis of anti-inflammatory and joint-protective effects.Frontiers in pharmacology · 2026Pooled it
- Comorbidity Profiles at Diagnosis in Rheumatoid Arthritis Versus Psoriatic Arthritis: A Nationwide Polish Claims-Based Study.Journal of clinical medicine · 2026Article
- Susceptibility to systemic autoimmunity rather than the presence of the HLA-DR4 peptide binding domain alone leads to severe inflammatory arthritis following inhalation of crystalline silica.Particle and fibre toxicology · 2026Article
- Rheumatoid Arthritis Management: Emerging Drug Therapies and Innovations.Current drug targets · 2026Review
- An overview of the role of the gut microbiota in rheumatoid arthritis.Microbiome research reports · 2026Review
- Molecular basis of post-translational neoantigen generation in rheumatoid arthritis: breaking immunological tolerance and implications for targeted therapy.Frontiers in immunology · 2026Review
- CAR-T and BiTE: new horizons in the treatment of rheumatic autoimmune diseases.Frontiers in immunology · 2026Review
- Carpal Tunnel Syndrome as an Early Underrecognized Feature of Rheumatoid Arthritis: A Population-Based Study of Carpal Tunnel Syndrome Occurrence Before and After Rheumatoid Arthritis Incidence.Arthritis care & research · 2025Article
- Cigarette Smoking: A Modifiable Environmental Factor in the Pathogenesis of Rheumatoid Arthritis.JMA journal · 2025Review
- Comorbidity in incident rheumatoid arthritis: a nationwide case-control study with bidirectional follow-up.Rheumatology (Oxford, England) · 2025Article
- Integrating electronic health records and GWAS summary statistics to predict the progression of autoimmune diseases from preclinical stages.Nature communications · 2025Article
- Suppression of Inflammation by Si Miao San in Experimental Rheumatoid Arthritis Through Modulation of the AKT/ROS/Autophagy Axis.Journal of inflammation research · 2025Article
- Trends in rheumatoid arthritis burden in China and globally, 1990-2021: A longitudinal study based on the GBD database.PloS one · 2025Article
- MSC-microvesicles protect cartilage from degradation in early rheumatoid arthritis via immunoregulation.Journal of nanobiotechnology · 2024Article
- Targeting Therapeutic Windows for Rheumatoid Arthritis Prevention.Chinese journal of integrative medicine · 2024Review
- Deciphering the different phases of preclinical inflammatory bowel disease.Nature reviews. Gastroenterology & hepatology · 2024Review
- Research progress of targeted therapy regulating Th17/Treg balance in bone immune diseases.Frontiers in immunology · 2024Review
- Life Events, Caregiving, and Risk of Autoimmune Rheumatic Diseases in the Women's Health Initiative Observational Study.Arthritis care & research · 2023Observational
- Human intestinal B cells in inflammatory diseases.Nature reviews. Gastroenterology & hepatology · 2023Review
- Signaling pathways in rheumatoid arthritis: implications for targeted therapy.Signal transduction and targeted therapy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
purpose of reviewThis review is to provide an update on the current understanding of rheumatoid arthritis (RA) development related to disease development prior to the onset clinically apparent synovitis (i.e. Pre-RA), and opportunities for disease prevention. RECENT
findingsA growing number of studies have demonstrated that serum elevations of autoantibodies rheumatoid factor, antibodies to citrullinated protein/peptide antigens (ACPAs) and antibodies to other posttranslationally modified proteins (e.g. carbamylated proteins) are highly predictive of future development of inflammatory arthritis/RA during a period that can be termed Pre-RA. Other factors including genetic, environmental, symptoms and imaging findings can also enhance prediction. Moreover, several novel biomarkers and changes in autoantibodies (e.g. glycosylation of variable domains) have been identified in Pre-RA. There has also been growing evidence that initiation and propagation of RA-related autoimmunity during the Pre-RA phase may be related to mucosal processes. The discovery of Pre-RA has also underpinned the development of several clinical prevention trials in RA; specifically, the PRAIRI study demonstrated that a single dose of rituximab can delay the onset of clinically apparent IA in at-risk individuals. Additional studies are evaluating the ability of drugs including abatacept, hydroxychloroquine and methotrexate to prevent or delay future RA. SUMMARY: The results from ongoing natural history and prevention trials in RA should further inform several critical issues in RA prevention including identification and enrolment of individuals at high-risk of imminent RA, the efficacy, safety and cost-effectiveness of prevention, and potentially the identification of new targets for prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.